We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

129 hedge funds and large institutions have $953M invested in Spyre Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 25

74% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $603K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

2.49% more ownership

Funds ownership: 103.07% → 105.56% (+2.5%)

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

0% more funds holding

Funds holding: 129 → 129 (0)

5% less capital invested

Capital invested by funds: $1B → $953M (-$51.7M)

Holders
129
Holders Change
–
Holders Change %
0%
% of All Funds
1.7%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
18
Increased
64
Reduced
25
Closed
17
Calls
$1.05M
Puts
$603K
Net Calls
+$446K
Net Calls Change
+$628K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$17M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.1M
3
BBA
Baker Bros. Advisors
New York
+$9.27M
4
BlackRock
BlackRock
New York
+$6.43M
5
Morgan Stanley
Morgan Stanley
New York
+$4.97M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$15.2M
2
PA
Perceptive Advisors
New York
-$11.6M
3
DCM
Driehaus Capital Management
Illinois
-$9.35M
4
PBA
Paradigm Biocapital Advisors
New York
-$3.8M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAA
26
Affinity Asset Advisors
New York
$9.08M +$1.85M +125,000 +26%
EA
27
Emerald Advisers
Pennsylvania
$8.47M +$267K +18,036 +3%
Goldman Sachs
28
Goldman Sachs
New York
$7.84M +$4.83M +326,348 +166%
Blackstone Inc
29
Blackstone Inc
New York
$7.32M – – –
WP
30
Woodline Partners
California
$6.96M +$5.09K +344 +0.1%
UBS Group
31
UBS Group
Switzerland
$6.93M -$1.32M -89,380 -16%
Northern Trust
32
Northern Trust
Illinois
$6.54M +$844K +57,072 +15%
Charles Schwab
33
Charles Schwab
California
$6.26M +$531K +35,867 +9%
Bank of America
34
Bank of America
North Carolina
$5.93M -$455K -30,724 -7%
SL
35
Siren LLC
Connecticut
$5.52M – – –
Victory Capital Management
36
Victory Capital Management
Texas
$5.3M +$1.51M +102,270 +41%
Capital World Investors
37
Capital World Investors
California
$5.25M – – –
EMFAT
38
Emerald Mutual Fund Advisers Trust
Pennsylvania
$4.93M -$888K -59,992 -15%
Voloridge Investment Management
39
Voloridge Investment Management
Florida
$4.18M +$318K +21,488 +8%
CS
40
Candriam SCA
Luxembourg
$3.68M – – –
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$3.34M +$2.48M +167,487 +300%
DTC
42
Deep Track Capital
Connecticut
$3.28M – – –
Barclays
43
Barclays
United Kingdom
$3.24M +$30.2K +2,040 +1%
CLGM
44
Capitolis Liquid Global Markets
New York
$2.74M +$2.71M +183,000 New
AC
45
Armistice Capital
New York
$2.57M -$414K -28,000 -14%
N
46
Nuveen
North Carolina
$2.02M -$74.9K -5,061 -4%
Bank of New York Mellon
47
Bank of New York Mellon
New York
$1.98M +$265K +17,910 +16%
Schroder Investment Management Group
48
Schroder Investment Management Group
United Kingdom
$1.97M +$312K +21,054 +19%
TD Asset Management
49
TD Asset Management
Ontario, Canada
$1.71M +$1.36M +91,600 +410%
HS
50
HighVista Strategies
Massachusetts
$1.69M +$261K +17,646 +19%
1
2
3 4 5

SYRE Hedge Fund Activity: Q2 2025 in Review

129 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2025, worth a combined $953M — down 5.1% from $1B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SYRE positions and 17 closed out — a net gain of 1 holder — while 64 added to existing stakes and 25 trimmed.

The largest buyer was Tang Capital Management, adding an estimated $17M. The largest seller was Janus Henderson Group, cutting an estimated $15.2M.

  • 129 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $953M of Spyre Therapeutics stock for Q2 2025, down 5.1% quarter-over-quarter.
  • 18 funds opened new Spyre Therapeutics positions in Q2 2025 and 17 closed out, a net change of +1 holder.
  • The largest Spyre Therapeutics buyer in Q2 2025 was Tang Capital Management, an estimated $17M added.
  • The largest Spyre Therapeutics seller in Q2 2025 was Janus Henderson Group, an estimated $15.2M sold.

Based on aggregated 13F filings for Q2 2025.